Nurix Therapeutics Inc NRIX Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$15.30 up $0.46, 3.10% at close Nov 6
Last close · Previous close $14.84
- Market cap
- At the Nov 6 close
- P/E ratio
- 6.65On last 12 months’ EPS
- Diluted EPS
- $2.30Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$15.30up $0.46, 3.10%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$14.84Nov 5
- Volume2.98MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume3.94MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $12.01 to $28.23; now $15.30
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
NRIX beat the S&P 500 in 2 of 6 periods.
| Period | NRIX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NRIX: down 32.3% S&P 500: down 5.6% | NRIX trailed the S&P 500 by 26.7 percentage points Trailed |
| 3M | NRIX: down 39.3% S&P 500: down 4.1% | NRIX trailed the S&P 500 by 35.2 percentage points Trailed |
| YTD | NRIX: down 19.3% S&P 500: up 8.7% | NRIX trailed the S&P 500 by 28.0 percentage points Trailed |
| 1Y | NRIX: up 22.2% S&P 500: up 10.9% | NRIX beat the S&P 500 by 11.3 percentage points Beat |
| Long term | ||
| 3Y | NRIX: up 159.1% S&P 500: up 75.0% +37.3% vs +20.5% a year | NRIX beat the S&P 500 by 84.1 percentage points Beat |
| 5Y | NRIX: down 55.0% S&P 500: up 67.8% −14.8% vs +10.9% a year | NRIX trailed the S&P 500 by 122.8 percentage points Trailed |
$10,000 invested in NRIX 5 years ago (Nov 5, 2021) would be worth about $4,500 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
NRIX beat the S&P 500 in 2 of 6 periods.
| Period | NRIX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NRIX: down 32.3% S&P 500: down 5.6% | NRIX trailed the S&P 500 by 26.7 percentage points Trailed |
| 3M | NRIX: down 39.3% S&P 500: down 4.3% | NRIX trailed the S&P 500 by 35.0 percentage points Trailed |
| YTD | NRIX: down 19.3% S&P 500: up 7.8% | NRIX trailed the S&P 500 by 27.1 percentage points Trailed |
| 1Y | NRIX: up 22.2% S&P 500: up 9.7% | NRIX beat the S&P 500 by 12.5 percentage points Beat |
| Long term | ||
| 3Y | NRIX: up 159.1% S&P 500: up 68.8% +37.3% vs +19.1% a year | NRIX beat the S&P 500 by 90.3 percentage points Beat |
| 5Y | NRIX: down 55.0% S&P 500: up 56.9% −14.8% vs +9.4% a year | NRIX trailed the S&P 500 by 111.9 percentage points Trailed |
$10,000 invested in NRIX 5 years ago (Nov 5, 2021) would be worth about $4,500 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$50.17
Closing high on . Now 69.5% below that record.
Split-adjusted daily closes since Jul 24, 2020.
Stock splits
NRIX hasn’t split since its price history begins in 2020.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Aug 31, 2026. “Last 12 months” means the four quarters from Sep 1, 2025 to Aug 31, 2026, and balance-sheet figures are as of Aug 31, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $701.94Mup 738.8%
- Net income
- $294.88M
- Diluted EPS
- $2.30
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Nov 30, 2024) | $13.28M | −$58.55M | −$0.75 |
| Q1 FY25 (Feb 28, 2025) | $18.45M | −$56.35M | −$0.67 |
| Q2 FY25 (May 31, 2025) | $44.06M | −$43.46M | −$0.52 |
| Q3 FY25 (Aug 31, 2025) | $7.89M | −$86.42M | −$1.03 |
| Q4 FY25 (Nov 30, 2025) | $13.58M | −$78.22M | −$0.83 |
| Q1 FY26 (Feb 28, 2026) | $6.25M | −$87.17M | −$0.79 |
| Q2 FY26 (May 31, 2026) | $9.04M | −$89.54M | −$0.81 |
| Q3 FY26 (Aug 31, 2026) | $673.06M | $549.81M | $4.73 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Nov 30, 2021) | $29.75M | −$117.19M | −$2.73 |
| FY22 (Nov 30, 2022) | $38.63M | −$180.36M | −$3.71 |
| FY23 (Nov 30, 2023) | $76.99M | −$143.95M | −$2.65 |
| FY24 (Nov 30, 2024) | $54.55M | −$193.57M | −$2.88 |
| FY25 (Nov 30, 2025) | $83.98M | −$264.46M | −$3.05 |
Margins
- Gross 100.0%
- Operating 41.3%
- Net 42.0%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $369.81MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$379.31MLast 12 months
- Capital spending$9.50MLast 12 months
- 52.7%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $261.21MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
0% of free cash flow
Balance sheet
- $1.06BAs of Aug 31, 2026
Cash plus short- and long-term marketable securities on the Aug 31, 2026 balance sheet.
- Total debt$65.33MAs of Aug 31, 2026
- Net cash$998.54MAs of Aug 31, 2026
- 8.44As of Aug 31, 2026
Current assets divided by current liabilities on the Aug 31, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.07As of Aug 31, 2026
Total debt divided by shareholders’ equity on the Aug 31, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 7 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 49.3%Last 12 months
Over the last 12 months, Nurix Therapeutics’s net income was 49.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 38.6%Last 12 months
Over the last 12 months, Nurix Therapeutics’s net income was 38.6% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Nurix Therapeutics Inc
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
NRIX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
NRIX stock FAQ
What is NRIX stock’s price today?
Nurix Therapeutics (NRIX) traded at $15.30 at the close on , up $0.46 (3.10%) from the previous close of $14.84. Over the past 52 weeks it has traded between $12.01 and $28.23.
If you invested $1,000 in NRIX 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in NRIX on would be worth about $450 at the close on , a total return of −55.0%. The same $1,000 would be worth $1,222 if invested one year ago. Past performance doesn’t predict future returns.
What is NRIX’s P/E ratio?
NRIX trades at 6.7 times its diluted earnings over the four quarters to ($2.30 per share), at the close. (How the P/E ratio works.)
How much revenue does Nurix Therapeutics make?
Nurix Therapeutics reported $701.9 million of revenue over the four quarters to , up 738.8% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $673.1 million, up 8,426.3% from a year earlier.
Is Nurix Therapeutics profitable?
Yes. Nurix Therapeutics earned $294.9 million of net income over the four quarters to , a net margin of 42.0%, and its operating margin was 41.3% (what margins tell you).
What are NRIX’s earnings per share?
NRIX’s diluted earnings per share were $2.30 over the four quarters to , compared with −$2.97 in the twelve months before. The latest quarter (Q3 FY26) brought $4.73 per share, against −$1.03 a year earlier (how EPS works).
Does NRIX pay a dividend?
Nurix Therapeutics hasn’t paid a dividend in the last twelve months.
What is NRIX’s 52-week high and low?
Over the past 52 weeks NRIX has traded as low as $12.01 and as high as $28.23. At $15.30 at the close on , it is 45.8% below that high and 27.4% above the low.
What is NRIX’s all-time high?
NRIX’s highest closing price was $50.17 on , adjusted for stock splits. At $15.30 at the close on , it is 69.5% below that record.
Has NRIX stock ever split?
No. NRIX hasn’t split since its price history begins in 2020.
How has NRIX stock performed?
Including dividends and measured to the close on , NRIX has returned −19.3% so far this year and +22.2% over the past year, and −55.0% over five years (−14.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Nurix Therapeutics in?
Nurix Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does NRIX trade on?
Nurix Therapeutics trades on the Nasdaq under the ticker symbol NRIX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.